Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 75

1.

Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection.

Gish RG, Leung NW, Wright TL, Trinh H, Lang W, Kessler HA, Fang L, Wang LH, Delehanty J, Rigney A, Mondou E, Snow A, Rousseau F.

Antimicrob Agents Chemother. 2002 Jun;46(6):1734-40.

PMID:
12019083
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study.

Gish RG, Trinh H, Leung N, Chan FK, Fried MW, Wright TL, Wang C, Anderson J, Mondou E, Snow A, Sorbel J, Rousseau F, Corey L.

J Hepatol. 2005 Jul;43(1):60-6. Epub 2005 Apr 11.

PMID:
15922478
[PubMed - indexed for MEDLINE]
3.

A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B.

Lim SG, Ng TM, Kung N, Krastev Z, Volfova M, Husa P, Lee SS, Chan S, Shiffman ML, Washington MK, Rigney A, Anderson J, Mondou E, Snow A, Sorbel J, Guan R, Rousseau F; Emtricitabine FTCB-301 Study Group.

Arch Intern Med. 2006 Jan 9;166(1):49-56.

PMID:
16401810
[PubMed - indexed for MEDLINE]
4.

Emtricitabine: a novel nucleoside reverse transcriptase inhibitor.

Molina JM, Cox SL.

Drugs Today (Barc). 2005 Apr;41(4):241-52. Review.

PMID:
16034488
[PubMed - indexed for MEDLINE]
5.

A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B.

Marcellin P, Mommeja-Marin H, Sacks SL, Lau GK, Sereni D, Bronowicki JP, Conway B, Trepo C, Blum MR, Yoo BC, Mondou E, Sorbel J, Snow A, Rousseau F, Lee HS.

Hepatology. 2004 Jul;40(1):140-8.

PMID:
15239097
[PubMed - indexed for MEDLINE]
6.

A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels.

Yalçin K, Değertekin H, Kokoğlu OF, Ayaz C.

Turk J Gastroenterol. 2004 Mar;15(1):14-20.

PMID:
15264116
[PubMed - indexed for MEDLINE]
7.

Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B.

Lim SG, Krastev Z, Ng TM, Mechkov G, Kotzev IA, Chan S, Mondou E, Snow A, Sorbel J, Rousseau F.

Antimicrob Agents Chemother. 2006 May;50(5):1642-8.

PMID:
16641430
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B.

Lim SG, Leung N, Hann HW, Lau GK, Trepo C, Mommeja-Marin H, Moxham C, Sorbel J, Snow A, Blum MR, Rousseau F, Marcellin P.

Aliment Pharmacol Ther. 2008 Jun;27(12):1282-92. doi: 10.1111/j.1365-2036.2008.03686.x. Epub 2008 Mar 22.

PMID:
18363895
[PubMed - indexed for MEDLINE]
9.

Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation.

Gane EJ, Angus PW, Strasser S, Crawford DH, Ring J, Jeffrey GP, McCaughan GW; Australasian Liver Transplant Study Group.

Gastroenterology. 2007 Mar;132(3):931-7. Epub 2007 Jan 5.

PMID:
17383422
[PubMed - indexed for MEDLINE]
10.

A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B.

Yuen MF, Kim J, Kim CR, Ngai V, Yuen JC, Min C, Kang HM, Shin BS, Yoo SD, Lai CL.

Antivir Ther. 2006;11(8):977-83.

PMID:
17302367
[PubMed - indexed for MEDLINE]
11.

Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.

Benhamou Y, Fleury H, Trimoulet P, Pellegrin I, Urbinelli R, Katlama C, Rozenbaum W, Le Teuff G, Trylesinski A, Piketty C; TECOVIR Study Group.

Hepatology. 2006 Mar;43(3):548-55.

PMID:
16496322
[PubMed - indexed for MEDLINE]
12.

Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil).

Rousseau FS, Kahn JO, Thompson M, Mildvan D, Shepp D, Sommadossi JP, Delehanty J, Simpson JN, Wang LH, Quinn JB, Wakeford C, van der Horst C.

J Antimicrob Chemother. 2001 Oct;48(4):507-13.

PMID:
11581229
[PubMed - indexed for MEDLINE]
Free Article
13.

Anti-hepatitis B virus activity of wogonin in vitro and in vivo.

Guo Q, Zhao L, You Q, Yang Y, Gu H, Song G, Lu N, Xin J.

Antiviral Res. 2007 Apr;74(1):16-24. Epub 2007 Jan 24.

PMID:
17280723
[PubMed - indexed for MEDLINE]
14.

Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.

Liu CJ, Chuang WL, Lee CM, Yu ML, Lu SN, Wu SS, Liao LY, Chen CL, Kuo HT, Chao YC, Tung SY, Yang SS, Kao JH, Liu CH, Su WW, Lin CL, Jeng YM, Chen PJ, Chen DS.

Gastroenterology. 2009 Feb;136(2):496-504.e3. doi: 10.1053/j.gastro.2008.10.049. Epub 2008 Oct 29.

PMID:
19084016
[PubMed - indexed for MEDLINE]
15.

Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.

Chan HL, Wong VW, Tse AM, Tse CH, Chim AM, Chan HY, Wong GL, Sung JJ.

Clin Gastroenterol Hepatol. 2007 Dec;5(12):1462-8.

PMID:
18054753
[PubMed - indexed for MEDLINE]
16.

Viral pharmacodynamic model for (-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine (emtricitabine) in chronically infected woodchucks.

Hurwitz SJ, Tennant BC, Korba BE, Liberman I, Gerin JL, Schinazi RF.

Antivir Chem Chemother. 2002 May;13(3):165-76.

PMID:
12448689
[PubMed - indexed for MEDLINE]
17.

Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C.

Fabris P, Brown D, Tositti G, Bozzola L, Giordani MT, Bevilacqua P, de Lalla F, Webster GJ, Dusheiko G.

J Clin Virol. 2004 Mar;29(3):160-6.

PMID:
14962784
[PubMed - indexed for MEDLINE]
18.

Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.

Lai CL, Rosmawati M, Lao J, Van Vlierberghe H, Anderson FH, Thomas N, Dehertogh D.

Gastroenterology. 2002 Dec;123(6):1831-8.

PMID:
12454840
[PubMed - indexed for MEDLINE]
19.

Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications.

Zhou XJ, Lim SG, Lloyd DM, Chao GC, Brown NA, Lai CL.

Antimicrob Agents Chemother. 2006 Mar;50(3):874-9.

PMID:
16495245
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks.

Cullen JM, Smith SL, Davis MG, Dunn SE, Botteron C, Cecchi A, Linsey D, Linzey D, Frick L, Paff MT, Goulding A, Biron K.

Antimicrob Agents Chemother. 1997 Oct;41(10):2076-82.

PMID:
9333028
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk